We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Abemaciclib Reduces Recurrence in High-Risk Hormone Receptor Positive Early Breast Cancer

News   Sep 21, 2020 | Original story from ESMO

 
Adding Abemaciclib to Hormonal Therapy Reduces Risk of Cancer Recurrence in Patients With High-Risk Early HR+ HER2- Early Breast Cancer
 
 
Advertisement
 

RELATED ARTICLES

The Genetic Architecture of Penicillin Allergy

News

Researchers announce the first robust evidence for the role of the major histocompatibility complex gene HLA-B in penicillin allergy to identify genetic risk factors for penicillin allergy.

READ MORE

Mapping the Immune Landscape in Pancreatic Cancer To Guide Immunotherapy

News

A new study led by the University of Michigan Rogel Cancer Center combined single-cell RNA sequencing with two other investigative techniques to create a network of interactions that suppress the body's immune response in and around pancreatic tumors.

READ MORE

Trial Will Investigate if Anti-Nausea Drug Can Alleviate Hallucinations in People With Parkinson's

News

Phase 2 clinical trial will explore if the drug ondansetron is safe and effective against hallucinations in patients with Parkinson's disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE